Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01851733 · ClinicalTrials.gov registry record · Phase 1
MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT01851733 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 37 participants.
The verdict
NCT01851733, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
This pilot clinical trial studies magnetic resonance imaging (MRI)-guided laser surgery (MLA) and doxorubicin hydrochloride in treating patients with recurrent glioblastoma multiforme. The blood brain barrier (BBB) is a separation of circulating blood from the tissue of the central nervous system, preventing substances in the blood from entering the brain. MLA disrupts the BBB around the tumor which may allow cancer-killing substances to be carried directly to the tumor and the surrounding area. Using MLA prior to chemotherapy may result in a greater concentration of drug in the tumor to kill the cancer cells while limiting side effects.
Interventions
- DRUG Doxorubicin
- DEVICE MRI-guided Laser Heat Ablation (MLA)
- OTHER Blood draw - dendritic cells
- DEVICE Dynamic Susceptibility Contrast Magnetic Resonance Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2013-08-13 |
| Est. Completion | 2018-05-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01851733
The ClinicalTrials.gov registry entry for NCT01851733 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Doxorubicin is the first listed.
NCT01851733 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01851733 about?
NCT01851733 is a clinical study titled "MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme". This pilot clinical trial studies magnetic resonance imaging (MRI)-guided laser surgery (MLA) and doxorubicin hydrochloride in treating patients with recurrent glioblastoma multiforme. The blood brain barrier (BBB) is a separation of circulating blood from the tissue of the central nervous system, p...
What is the current status of trial NCT01851733?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2013-08-13. Estimated completion is 2018-05-30.
What interventions are being tested in trial NCT01851733?
The interventions under investigation include: Doxorubicin (DRUG), MRI-guided Laser Heat Ablation (MLA) (DEVICE), Blood draw - dendritic cells (OTHER), Dynamic Susceptibility Contrast Magnetic Resonance Imaging (DEVICE).
Who is sponsoring clinical trial NCT01851733?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.